Suchergebnisse - "Vasudevan, Abhinav"

PubPharm (7)

1

Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease

enthalten in: Medicina (Kaunas, Lithuania) | 2024

von Dutt, K. | Vasudevan, A.

2

Response to : Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlate With Rate of Infection

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2021

von Con, D. | Van Langenberg, D. | Vasudevan, A.

CommentOn: Clin Gastroenterol Hepatol. 2021 Feb;19(2):288-295.e4. - PMID 32200087

3

Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab : A stepwise, safety and patient-orientated process towards sustainability

enthalten in: World journal of gastroenterology | 2020

von Bohra, A. | Rizvi, Q. | Keung, C. | +2

4

Poor Bowel Preparation in Crohn's Disease

enthalten in: Gastroenterology | 2020

von Apostolov, R. | Tan, N. | Vasudevan, A.

5

Letter : overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it!

enthalten in: Alimentary pharmacology & therapeutics | 2018

von van Langenberg, D. | Vasudevan, A.

CommentOn: Aliment Pharmacol Ther. 2018 Feb;47(3):346-355. - PMID 29226370

6

Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease

enthalten in: Journal of Crohn's & colitis | 2018

von Srinivasan, A. | Vasudevan, A. | McFarlane, A. | +3

7

Time to clinical response and remission for therapeutics in inflammatory bowel diseases : What should the clinician expect, what should patients be told?

enthalten in: World journal of gastroenterology | 2017

von Vasudevan, A. | Gibson, P. | van Langenberg, D.

1
[1]